Systems biology-based drug repurposing for neuroinflammation treatment in activated human microglia
Martina Cirinciani, Lorenzo Germelli, Eleonora Da Pozzo, Corrado Priami, Claudia Martini, Paolo Milazzo · 2026
Read Systems biology-based drug repurposing for neuroinflammation treatment in activated human microglia by Martina Cirinciani, Lorenzo Germelli, Eleonora Da Pozzo, Corrado Priami, Claudia Martini, Paolo Milazzo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13482100.txt.
Description
Cirinciani and colleagues used a systems biology network in 2026 to find existing drugs that might calm neuroinflammation, the brain immune activation shared by many degenerative and psychiatric diseases. Their pipeline linked genes, proteins, and drugs into one map of human neuroinflammation, then scored each drug by its position in the network and the jobs its target proteins perform. Microglia, the brain's resident immune cells, sat at the center of the search.
One candidate rose to the top: fostamatinib, a drug whose active form, R406, blocks the Syk signaling pathway inside immune cells in the body. The team tested R406 in two different laboratory models of human microglia pushed into an inflammatory state for the experiment. In both models the compound pushed back the pro-inflammatory response, supporting the network's prediction and giving the authors a concrete lead for repurposing an approved drug toward brain inflammation.
Catalog record
| CREATOR | Martina Cirinciani, Lorenzo Germelli, Eleonora Da Pozzo, Corrado Priami, Claudia Martini, Paolo Milazzo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |